Todd Rider
About Todd Rider
Todd Rider is the Director of Statistical Programming - Immunology, Cardiovascular, Fibrosis at Bristol Myers Squibb in Lawrenceville, NJ, with extensive experience in statistical programming and regulatory submissions.
Company
Todd Rider currently works at Bristol Myers Squibb, a global biopharmaceutical company known for its dedication to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases.
Title
Todd Rider holds the position of Director of Statistical Programming in the Immunology, Cardiovascular, Fibrosis division at Bristol Myers Squibb in Lawrenceville, NJ.
Education and Expertise
Todd Rider earned a Bachelor of Science (BS) in Mathematics from Bloomsburg University of Pennsylvania, where he studied from 1990 to 1994. His expertise includes statistical programming, regulatory submissions, and project management. He is a subject matter expert on FDA and PMDA CDISC submissions and has extensive experience leading statistical/SAS programming teams.
Professional Background
Todd Rider has a long-standing career with Bristol Myers Squibb, spanning various roles and locations since 1996. His roles have included Director of Statistical Programming, Associate Director II, and Senior Manager, among others, with responsibilities across multiple therapeutic areas such as Oncology and HIV. Prior to his tenure at Bristol Myers Squibb, he worked at Novo Nordisk as a SAS Programmer and at Trilogy Consulting Corporation as a Statistical Programmer.
Achievements
Todd Rider led the implementation of Pinnacle 21 Enterprise into work practices at Bristol Myers Squibb and played a key role in the OneClinical Initiative. He has over five years of experience in enterprise improvement initiatives such as the End-to-End Clinical Data Chain Initiative. He also served as a technical representative for FDA meetings regarding Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE) submissions and labels. His contributions have supported Oncology (Opdivo, Yervoy) and HIV (Reyataz) projects through regulatory NDA and BLA submissions.